113.38
-0.42 (-0.37%)
| Penutupan Terdahulu | 113.80 |
| Buka | 113.50 |
| Jumlah Dagangan | 58,748 |
| Purata Dagangan (3B) | 119,072 |
| Modal Pasaran | 2,142,360,448 |
| Harga / Pendapatan (P/E TTM) | 45.53 |
| Harga / Pendapatan (P/E Ke hadapan) | 21.37 |
| Harga / Jualan (P/S) | 14.97 |
| Harga / Buku (P/B) | 2.79 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 25 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | 29.68% |
| Margin Operasi (TTM) | 21.14% |
| EPS Cair (TTM) | 2.49 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 57.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.88% |
| Nisbah Semasa (MRQ) | 12.49 |
| Aliran Tunai Operasi (OCF TTM) | 76.64 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 16.96 M |
| Pulangan Atas Aset (ROA TTM) | 1.30% |
| Pulangan Atas Ekuiti (ROE TTM) | 6.00% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Ligand Pharmaceuticals Incorpor | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.13 |
|
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.89% |
| % Dimiliki oleh Institusi | 100.37% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Congress Asset Management Co | 30 Sep 2024 | 604,038 |
| Ashford Capital Management Inc | 30 Sep 2024 | 310,407 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 160.00 (Barclays, 41.12%) | Beli |
| Median | 147.00 (29.65%) | |
| Rendah | 135.00 (Benchmark, 19.07%) | Beli |
| Purata | 148.40 (30.89%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 119.80 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Benchmark | 23 Dec 2024 | 135.00 (19.07%) | Beli | 113.80 |
| 08 Nov 2024 | 135.00 (19.07%) | Beli | 121.25 | |
| Barclays | 16 Dec 2024 | 160.00 (41.12%) | Beli | 122.34 |
| 08 Nov 2024 | 150.00 (32.30%) | Beli | 121.25 | |
| RBC Capital | 11 Dec 2024 | 143.00 (26.12%) | Beli | 120.36 |
| 12 Nov 2024 | 140.00 (23.48%) | Beli | 120.74 | |
| HC Wainwright & Co. | 08 Nov 2024 | 157.00 (38.47%) | Beli | 121.25 |
| 31 Oct 2024 | 157.00 (38.47%) | Beli | 105.70 | |
| Oppenheimer | 08 Nov 2024 | 147.00 (29.65%) | Beli | 121.25 |
| 03 Oct 2024 | 135.00 (19.07%) | Beli | 102.24 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 10 Dec 2024 | Pengumuman | Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance |
| 14 Nov 2024 | Pengumuman | Ligand to Present at Stifel 2024 Healthcare Conference |
| 07 Nov 2024 | Pengumuman | Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance |
| 01 Nov 2024 | Pengumuman | Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston |
| 23 Oct 2024 | Pengumuman | Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 |
| 17 Oct 2024 | Pengumuman | Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |